STOCK TITAN
  1. Home
  2. News
  3. SOPH

SOPHiA Genetics SA - SOPH STOCK NEWS

Welcome to our dedicated news page for SOPHiA Genetics SA (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA Genetics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOPHiA Genetics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOPHiA Genetics SA's position in the market.

News
The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), is now live on the SOPHiA DDM™ Platform to advance its research into rare disorders, particularly male fertility. IHG PAS will use SOPHiA DDM™ Whole Exome Solution (WES) for next-generation sequencing (NGS) to accelerate research of inherited diseases, including infertility. The platform provides overnight analysis of WES and a rich knowledge base to help identify variants of interest associated with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023
Rhea-AI Summary
SOPHiA GENETICS SA (Nasdaq: SOPH) reported financial results for Q3 2023, with revenue of $16.3 million, a 40% YoY growth. Operating loss improved by 30% YoY, and cash burn decreased to $15.8 million. The company reaffirmed its full-year guidance, expecting revenue growth of at least 30% and operating losses below 2022 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
earnings
-
News
SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023
Rhea-AI Summary
SOPHiA GENETICS SA to release Q3 2023 financial results on November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.51%
Tags
earnings
-
News
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
Rhea-AI Summary
SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca collaborate to improve global access to cancer testing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
News
Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders
Rhea-AI Summary
Shaare Zedek Medical Center implements SOPHiA DDM™ Platform for myeloid disorders research and precision medicine development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
-
News
Laboratorio Curie Expands Relationship with SOPHiA GENETICS
Rhea-AI Summary
SOPHiA GENETICS expands its relationship with Laboratorio Curie to advance research on BRCA gene mutations. Laboratorio Curie will use the SOPHiA DDM™ Platform for NGS testing, providing accurate results in less than two days. This will support investigations into BRCA-associated cancers and enable the Lab to amass a database of BRCA research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.94%
Tags
none
-
News
SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
Rhea-AI Summary
SOPHiA GENETICS introduces new diagnostic kit for advanced ovarian cancer, aiding in personalized treatment plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.44%
Tags
none
News
CHU Bordeaux is live on SOPHiA GENETICS
Rhea-AI Summary
CHU Bordeaux hospital adopts SOPHiA DDM™ Platform for research on HRR-mutated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
Stock SOPH logo
SOPHiA Genetics SA

Nasdaq:SOPH

SOPH Rankings

#3343 Ranked by Market Cap
#276 Ranked by Stock Gains
N/A Ranked by Dividends

SOPH Stock Data

326.51M
46.15M
5.92%
49.96%
0.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Rolle

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based